Hormone therapy and menopause;Hormontherapie und menopause

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 13, 2005, Pages 829-834

  Heutling, D ^a   Lehnert, H ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO;

BREAST CARCINOMA; COLORECTAL CARCINOMA; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; MONOTHERAPY; OSTEOPOROSIS; PRIMARY PREVENTION; QUALITY OF LIFE; REVIEW; SUBSTITUTION THERAPY; THROMBOEMBOLISM;

AGED; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS; QUALITY OF LIFE; RISK FACTORS;

EID: 17144401557     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-865097     Document Type: Review

References (33)

1. Anderson GL, Limacher M, Assaf AR et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-1712
2. Beral V Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427
3. Brass LM. Hormone replacement therapy and stroke: clinical trials review. Stroke 2004; 35: 2644-2647
4. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR Study of Osteoporotic Fractures Research Group. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. JAMA 1996; 276: 1404-1408
5. Cauley JA, Robbins J, Chen Z et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1729-1738
6. Cherry N, Gilmour K, Hannaford P et al. ESPRIT team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002; 360: 2001-2008
7. Chlebowski RT, Hendrix SL, Langer RD et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289: 3243-3253
8. Col NF, Weber G, Stiggelbout A, Chuo J, D'Agostino R, Corso P. Short-term menopausal hormone therapy for symptom relief: an updated decision model. Arch Intern Med 2004; 164: 1634-1640
9. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047-1059
10. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2004; online publication
11. Gambacciani M. New HRT Options for the Treatment of Menopausal Symptoms and the Maintenance of Quality of Life in Postmenopausal Women. Endocrine 2004; 24: 231-238
12. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann intern Med 1992; 117: 1016-1037
13. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933-941
14. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004; 140: 184-188
15. Hays J, Ockene JK, Brunner RL, Kotchen JM et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348: 1839-1854
16. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151: 75-78
17. Hodis HN, Mack WJ, Lobo RA et al. Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135: 939-953
18. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999; 84: 4559-4565
19. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613
20. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002; 137: 273-284
21. Lahmann PH, Hoffmann K, Allen N et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 2004; 111: 762-771
22. Löwel H, Heier M, Schneider A, Gösele U, Meisinger C. Hormontherapie (II): Vergleiche sind zulässig. Deutsches Ärzteblatt 2003; 100: A2561-2562
23. Manson JE, Hsia J, Johnson KC et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523-534
24. 24 Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 1996; 143: 971-978.
25. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-1811
26. Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US Preventive Services Task Force. Ann Intern Med 2002; 136: 680-690
27. Psaty BM, Heckbert SR, Atkins D et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154: 1333-1339
28. Pressemitteilungdes BfARM vom 06.05.2004: http://bfarm.de,
29. Rossouw JE, Anderson GL, Prentice RL et al. Women's Health Initiative Investigators. Writing Group for the Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333
30. Scarabin PY, Oger E, Plu-Bureau G. EStrogen and THromboEmbolism Risk Study Group Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-432
31. Wassertheil-Smoller S, Hendrix SL, Limacher et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289: 2673-2684
32. Writing group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995; 273: 199-208
33. Zhang Y, Kiel DP, Kreger BE et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 1997; 336: 611-617